泰格医药(300347.SZ)逼近160元再创历史新高 年内累涨超150% 市值逼近1400亿
格隆汇12月24日丨泰格医药(300347.SZ)今日收涨3.32%报159.4元,盘中再创历史新高价159.48元,最新市值1376亿元。H股今日收涨0.98%报175港元,盘中创上市新高价178港元。泰格医药是国内临床CRO龙头企业,截至2019年数据,泰格医药在国内临床CRO市场份额高达8.4%。数据显示,泰格医药2010年营收1.23亿元,2019年增长至28.03亿元,九年营收增长21.78倍,复合年化增长率为41.52%;2010年扣非净利润0.32亿元,2019年增长至8.42亿元,九年增长25.31倍,复合年化增长率高达43.81%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.